Oncotarget

Research Papers:

Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus

Shao-Lian Wang, Wen-Bin Dong, Xiao-Lin Dong _, Wen-Min Zhu, Fang-Fang Wang, Fang Han and Xin Yan

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:72700-72713. https://doi.org/10.18632/oncotarget.20282

Metrics: PDF 1596 views  |   HTML 2541 views  |   ?  


Abstract

Shao-Lian Wang1, Wen-Bin Dong2, Xiao-Lin Dong1, Wen-Min Zhu1, Fang-Fang Wang1, Fang Han1 and Xin Yan1

1Department of Endocrinology, Jinan Central Hospital, Jinan 250013, P.R. China

2Pharmaceutical Preparation Section, Jinan Central Hospital, Jinan 250013, P.R. China

Correspondence to:

Xiao-Lin Dong, email: [email protected]

Keywords: type 2 diabetes mellitus, single-drug regimen, effects, randomized controlled trials, network meta-analysis

Received: March 29, 2017    Accepted: July 18, 2017    Published: August 16, 2017

ABSTRACT

We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from these studies was combined, and weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRAs) were examined to evaluate the monotherapies. Liraglutide was more effective than Glimepiride, Pioglitazone, Sitaglitin, Exenatide, and Glipizide at reducing glycated hemoglobin (HbA1c) levels. In contrast, Acarbose was less effective than Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, and Liraglutide at decreasing HbA1c levels. Reductions in fasting plasma glucose (FPG) levels were similar after all treatments. Rosiglitazone was less effective than Glibenclamide and Repaglinide at reducing total cholesterol (TC) levels. High density lipoprotein (HDL), low density lipoprotein (LDL), and triglyceride levels did not differ after treatment with any of the monotherapies. HbA1c and FPG SUCRA values were highest for Liraglutide, while HbA1c and FPG values were lowest for Acarbose, and TC and LDL values were lowest for Rosiglitazone. These results suggest that Liraglutide may be most effective, and Acarbose least effective, at reducing blood glucose levels, while Glibenclamide, Repaglinide, and Metformin may be most effective, and Rosiglitazone least effective, at reducing lipoidemia, in T2DM patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20282